LONDON- AstraZeneca PLC's new drug application for LYNPARZA tablets for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting has been accepted for priority review by the US Food& Drug Administration- with a decision expected in the third quarter 2017.. In clinical trials, LYNPARZA demonstrated a median Progression
By a News Reporter-Staff News Editor at Biotech Week Fresh data on Neurodegenerative Diseases and Conditions are presented in a new report. According to news reporting originating from Taipei, Taiwan, by NewsRx correspondents, research stated, "Chronic brain stimulation has become a promising physical therapy with increased efficacy and efficienc
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration approved OCREVUS? as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The FDA s approval of OCREVUS is the beginning of a new era for the MS community and represents a significant scientific a
Basel Roche announced today that the US Food and Drug Administration approved OCREVUS (TM) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. "The FDA's approval of OCREVUS is the beginning of a new era for the MS community and represents a significant scientific advance with this first-in-clas
Findings in the Area of Transdermal Delivery Reported from Assiut University. According to news reporting from Assiut, Egypt, by NewsRx journalists, research stated, "Glibenclamide nanocrystals were engineered by applying combined precipitation and homogenization procedures. The news correspondents obtained a quote from the research from Assiut...
By a News Reporter-Staff News Editor at Biotech Week Investigators publish new report on Drugs and Therapies- Drug Delivery Systems. According to news originating from Chengdu, People's Republic of China, by NewsRx correspondents, research stated, "To alleviate the hemorrhagic side effect of thrombolysis therapy, a thrombus targeted drug delivery
New Drug Delivery Systems Findings Has Been Reported by Researchers at University of Maryland. According to news reporting out of College Park, Maryland, by NewsRx editors, research stated, "We report the ability of hydrophobically modified polypeptoids, which are amphiphilic pseudopeptidic macromolecules, to connect across lipid bilayers and thus
New Findings from M.S. El-Ridy and Co-Authors in the Area of Transdermal Delivery Reported. By a News Reporter-Staff News Editor at Biotech Week Investigators publish new report on Drugs and Therapies- Transdermal Delivery. According to news reporting from Cairo, Egypt, by NewsRx journalists, research stated, "The objective of this study was to i
New Findings on Drug Delivery Systems Described by Investigators at University of Maribor. Our news journalists obtained a quote from the research from the University of Maribor, "The attachment of the chitosan nanoparticles to the fiber surface was studied by evaluation of the quantity of chitosan amino groups using a conventional spectrophotometr
According to news reporting from Fisciano, Italy, by NewsRx journalists, research stated, "Coated pellets are widely used as oral drug delivery systems, being highly accepted by patients and with several advantages with respect to single unit devices. For more information on this research see: Mathematical modeling of the drug release from an ensem
Research and Markets has announced the addition of the "Patch Pump Drug Delivery Systems Devices Therapeutics Markets Forecasts" report to their offering. This report analyzes important therapeutic segments and examines key regulatory, economic and competitive factors that represent potential barriers to commercial success. Patch Pump Drug Delivery
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by the inventor KANIOS, DAVID, filed on April 6, 2016, was made available online on March 16, 2017. The assignee for this patent application is Noven Pharmaceuticals, Inc.. Reporters obtai
Patent Application Titled "Inductively Rechargeable External Energy Source, Charger, System and Method for a Transcutaneous Inductive Charger for an Implantable Medical Device" Published Online. By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent appli
By a News Reporter-Staff News Editor at Biotech Week- Portal Instruments, a clinical stage medical device start-up company based in Cambridge, MA received the SXSW Interactive Innovation Award in the Health, Med& Biotech category at the 20th annual South by Southwest Interactive Innovations Awards ceremony. The award was in recognition of Portal.
Pharmalink AB, a specialty pharma company, announces that positive results and analyses from the completed Phase 2 b trial of its oral drug candidate Nefecon in primary IgA nephropathy patients have been published online in The Lancet. This is the first time the full results from this trial have been published in this format. Johan Hggblad, CE
Studies from C. Corbo and Co-Researchers in the Area of Drug Delivery Systems Reported. By a News Reporter-Staff News Editor at Biotech Week New research on Drugs and Therapies- Drug Delivery Systems is the subject of a report. Funders for this research include European Regional Development Fund, Hearst Foundations, Ministero della Salute, Cancer
TESARO, an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration has approved ZEJULA, an oral, once-daily poly polymerase inhibitor, for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to...
LONDON- AstraZeneca said that the US Food and Drug Administration has accepted the company's New Drug Application or NDA for LYNPARZA tablets for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting. The FDA has also granted priority review status with a Prescription Drug User Fee Act set for third quarter 2017.
AstraZeneca today announced that the US Food and Drug Administration has accepted the company s New Drug Application for LYNPARZA? tablets for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting. The FDA grants Priority Review to applications for medicines that treat serious conditions and, if approved, would
Data on Drug Delivery Systems Discussed by Researchers at University of Girona. By a News Reporter-Staff News Editor at Cancer Weekly New research on Drugs and Therapies- Drug Delivery Systems is the subject of a report. Our news journalists report that additional information may be obtained by contacting J. Ciurana, Dept. of Mechanical Engineeri
Data on Drug Delivery Systems Reported by Researchers at Tabriz University of Medical Sciences. By a News Reporter-Staff News Editor at Cancer Weekly A new study on Drugs and Therapies- Drug Delivery Systems is now available. Our news editors obtained a quote from the research from the Tabriz University of Medical Sciences, "The PubMed database w
Global Home Healthcare Market Set for Rapid Growth, To Reach Around USD 300.0 Billion by 2020 Deerfield Beach, FL 03/28/2017 Zion Market Research has published a new report titled " Global Home Healthcare Market for Rehabilitation, Telehealth and Telemedicine, Respiratory Therapy, Infusion Therapy and Unskilled Home Healthcare Services: Globa
Unless otherwise indicated or the context otherwise requires, the words, "IntelGenx", "Company", "we", "us", and "our" refer to IntelGenx Technologies Corp. and its subsidiaries, including IntelGenx Corp. This information should be read in conjunction with the accompanying audited Consolidated Financial Statements and Notes thereto. We are a drug d
Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases caused by hormone dysregulation, today announced the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of a novel oral drug candidate, ATR-101, in patients with endogenous Cushing s syndrom
Shares of Cempra are down 5% mid-morning after the company said that it has withdrawn its marketing authorization application seeking European Medicines Agency approval of oral capsule and intravenous formulations of solithromycin for the treatment of community-acquired pneumonia in adults. Cempra, Inc. is a clinical-stage pharmaceutical company...